AccueilInfos pratiques & communicationsActualitésCARB-X funds novel antibiotics against ESKAPE pathogens

CARB-X funds novel antibiotics against ESKAPE pathogens

Partager l'article
Partager sur email
Partager sur twitter
Partager sur linkedin
Crédit : Pixabay

 Mentions: CARB-X, BioVersys, antibiotics, drugs, AMR, SNIPR Biome, CRISPR, microbiome
 
June 2, 2021 — CARB-X announced Tuesday that it will give Swiss biopharma BioVersys up to $4.3 million (plus up to $11 million in milestones) to develop new antibiotics to treat life-threatening infections caused by multidrug-resistant “ESKAPE” pathogens, including E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa and Enterobacter species.
 
BioVersys’ novel class of pyrrolocytosine small molecules have exhibited “robust coverage” of all relevant Gram-negative pathogens as well as other bacteria in preclinical studies, the press release said.
 
In other CARB-X news, the Boston University-led nonprofit announced last week that it will give Copenhagen-based SNIPR Biome up to $3.9 million (plus up to $6.3 million in milestones) to develop its SNIPR001 CRISPR-based drug candidate, which aims to prevent E. coli infections in cancer patients without harming beneficial bacteria in their microbiomes.
 
MORE INFORMATION:
 
CARB-X press release (BioVersys)
CARB-X press release (SNIPR Biome)